Potential cost-effectiveness of wearable cardioverter-defibrillator for patients with implantable cardioverter-defibrillator explant in a high-income city of China
- PMID: 31502350
- DOI: 10.1111/jce.14153
Potential cost-effectiveness of wearable cardioverter-defibrillator for patients with implantable cardioverter-defibrillator explant in a high-income city of China
Abstract
Introduction: Wearable cardioverter-defibrillator (WCD) is recommended for patients with implantable cardioverter-defibrillator (ICD) removal. This study aimed to investigate the potential cost-effectiveness of WCD for patients with ICD explant in a high-income city of China.
Methods and results: A 5-year decision-analytic model was developed to simulate outcomes of three strategies during the period between ICD explant and reimplantation: discharge-to-home without WCD (home group), discharge-to-home with WCD (WCD group), and stay-in-hospital (hospital group). Outcome measures were mortality rates (during the period between ICD explant and reimplantation), direct medical costs, quality-adjusted life years (QALYs), and incremental cost per QALY saved (ICER). Model inputs were derived from literature and public data. Base-case analysis was performed at four cost levels of WCD. Robustness of model results was examined by sensitivity analyses. In base-case analysis, the 8-week mortality rates of WCD, hospital, and home groups were 7.3%, 8.1%, and 9.4%, respectively. WCD group gained the highest QALYs (3.0990 QALYs), followed by hospital group (3.0553 QALYs) and home group (3.0132 QALYs). The WCD group was the cost-effective option with ICERs less than willingness-to-pay (WTP) threshold (57 315 USD/QALY) at WCD daily cost ≤USD48. In probabilistic sensitivity analysis, the WCD group at daily cost of USD24, USD48, USD72, and USD96 were cost-effective in 100%, 94.16%, 22.08%, and 0.16% of 10 000 Monte Carlo simulations, respectively.
Conclusions: Use of WCD during the period between ICD explant and reimplantation is likely to save life and gain higher QALYs. Cost-effectiveness of WCD is highly subject to the daily cost of WCD in China.
Keywords: China; cost-effectiveness; implantable cardioverter-defibrillator; sudden cardiac arrest; wearable cardioverter-defibrillator.
© 2019 Wiley Periodicals, Inc.
Similar articles
-
Wearable cardioverter-defibrillator for prevention of sudden cardiac death after infected implantable cardioverter-defibrillator removal: A cost-effectiveness evaluation.Heart Rhythm. 2015 Jul;12(7):1565-73. doi: 10.1016/j.hrthm.2015.03.061. Epub 2015 Mar 31. Heart Rhythm. 2015. PMID: 25839113
-
Wearable cardioverter-defibrillators in pediatric cardiomyopathy: A cost-utility analysis.Heart Rhythm. 2020 Feb;17(2):287-293. doi: 10.1016/j.hrthm.2019.08.028. Epub 2019 Aug 30. Heart Rhythm. 2020. PMID: 31476408
-
Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing ICD explant procedures: Clinical and economic implications.Clin Cardiol. 2021 Nov;44(11):1497-1505. doi: 10.1002/clc.23709. Epub 2021 Aug 24. Clin Cardiol. 2021. PMID: 34427926 Free PMC article.
-
Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant: Results From the National Registry.JACC Clin Electrophysiol. 2017 Mar;3(3):243-250. doi: 10.1016/j.jacep.2016.09.002. Epub 2016 Nov 23. JACC Clin Electrophysiol. 2017. PMID: 29759518
-
Wearable cardioverter-defibrillators: A review of evidence and indications.Trends Cardiovasc Med. 2021 Apr;31(3):196-201. doi: 10.1016/j.tcm.2020.03.002. Epub 2020 Mar 12. Trends Cardiovasc Med. 2021. PMID: 32205034 Review.
Cited by
-
Economic Perspective of the Use of Wearables in Health Care: A Systematic Review.Mayo Clin Proc Digit Health. 2024 May 14;2(3):299-317. doi: 10.1016/j.mcpdig.2024.05.003. eCollection 2024 Sep. Mayo Clin Proc Digit Health. 2024. PMID: 40206120 Free PMC article. Review.
-
Handling SCD risk in adult congenital heart disease: Should we InVEST in the WCD?Indian Pacing Electrophysiol J. 2022 Sep-Oct;22(5):223-224. doi: 10.1016/j.ipej.2022.08.004. Indian Pacing Electrophysiol J. 2022. PMID: 36064259 Free PMC article. No abstract available.
-
Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.Sensors (Basel). 2022 Mar 5;22(5):2037. doi: 10.3390/s22052037. Sensors (Basel). 2022. PMID: 35271182 Free PMC article.
-
Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for <90 Wear Days versus ≥90 Wear Days.In Vivo. 2020 Nov-Dec;34(6):3601-3610. doi: 10.21873/invivo.12205. In Vivo. 2020. PMID: 33144474 Free PMC article.
-
Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England.Pharmacoecon Open. 2025 Mar;9(2):301-312. doi: 10.1007/s41669-024-00553-z. Epub 2025 Jan 24. Pharmacoecon Open. 2025. PMID: 39849296 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical